Trial Profile
Open-label, Single Center Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Biodistribution in Pathological Tissue in Patients With Cancer or Inflammation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BAY 869596 (Primary)
- Indications Brain cancer; Brain metastases; Breast cancer; Cancer; Colorectal cancer; Inflammation; Liver cancer; Malignant melanoma; Ovarian cancer; Prostate cancer
- Focus Diagnostic use
- Sponsors Life Molecular Imaging
- 14 Nov 2014 New trial record